-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20

Benzinga·05/07/2026 11:54:21
Listen to the news
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $24 to $20.